FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2338861831> ?p ?o ?g. }

• W2338861831 abstract "In Vitro Characterization of the Percutaneous Absorption of Lorazepam into Human Cadaver Torso Skin, Using the Franz Skin Finite Dose Models Objective Lorazepam is a sedative that may be used for the management of anxiety, insomnia, and chemotherapy-induced nausea and vomiting. Lorazepam can be incorporated into transdermal bases such as Lipoderm, referred to as Phospholipid Base, for drug delivery across the skin. The purpose of this study is to characterize the percutaneous absorption of lorazepam 5 mg/g in Phospholipid Base, when applied to human cadaver torso skin, in vitro, using the Franz skin finite dose model. Methods The percutaneous absorption of lorazepam was evaluated using ex vivo human cadaver torso skin from 3 donors. The skin from each donor was cut into small sections to fit on nominal 2 cm2 Franz diffusion cells. A nominal volume equivalent to 5 mg formulation/cm2/skin section was then applied to a 2 cm2 dosing surface of 3 replicate skin sections for each donor. At predetermined time points (0, 2, 4, 8, 12, 24, 32, and 48 hr), the receptor solution within each chamber was removed, replaced with fresh receptor solution, and an aliquot of 6 mL was saved for analysis. Mean values for lorazepam total absorption, rate of absorption, skin content, and surface wash were quantified via HPLC analysis. Results Lorazepam mean total absorption was 8.38% ± 4.37, with a rise to peak rate of absorption at approximately 30 hr following dose application. Lorazepam was also found within the dermis and epidermis at 0.22% ± 0.02 and 3.65% ± 1.29 of the applied dose, respectively. Conclusion Results show that Phospholipid Base can facilitate the percutaneous absorption of lorazepam. This study’s findings may be helpful when justifying the viability of using Phospholipid Base as a vehicle for the transdermal delivery of lorazepam and could potentially be useful for practitioners and pharmacists considering the skin as an alternative route for the delivery of lorazepam." @default.
• W2338861831 created "2016-06-24" @default.
• W2338861831 creator A5023450003 @default.
• W2338861831 creator A5067825841 @default.
• W2338861831 date "2015-01-01" @default.
• W2338861831 modified "2023-10-18" @default.
• W2338861831 title "In Vitro Characterization of the Percutaneous Absorption of Lorazepam into Human Cadaver Torso Skin, Using the Franz Skin Finite Dose Models" @default.
• W2338861831 doi "https://doi.org/10.4172/2325-9604.1000131" @default.
• W2338861831 hasPublicationYear "2015" @default.
• W2338861831 type Work @default.
• W2338861831 sameAs 2338861831 @default.
• W2338861831 citedByCount "7" @default.
• W2338861831 countsByYear W23388618312016 @default.
• W2338861831 countsByYear W23388618312021 @default.
• W2338861831 crossrefType "journal-article" @default.
• W2338861831 hasAuthorship W2338861831A5023450003 @default.
• W2338861831 hasAuthorship W2338861831A5067825841 @default.
• W2338861831 hasBestOaLocation W23388618311 @default.
• W2338861831 hasConcept C125287762 @default.
• W2338861831 hasConcept C159985019 @default.
• W2338861831 hasConcept C185592680 @default.
• W2338861831 hasConcept C192562407 @default.
• W2338861831 hasConcept C205679159 @default.
• W2338861831 hasConcept C2777459323 @default.
• W2338861831 hasConcept C2779706987 @default.
• W2338861831 hasConcept C42219234 @default.
• W2338861831 hasConcept C54355233 @default.
• W2338861831 hasConcept C71924100 @default.
• W2338861831 hasConcept C86803240 @default.
• W2338861831 hasConcept C98274493 @default.
• W2338861831 hasConceptScore W2338861831C125287762 @default.
• W2338861831 hasConceptScore W2338861831C159985019 @default.
• W2338861831 hasConceptScore W2338861831C185592680 @default.
• W2338861831 hasConceptScore W2338861831C192562407 @default.
• W2338861831 hasConceptScore W2338861831C205679159 @default.
• W2338861831 hasConceptScore W2338861831C2777459323 @default.
• W2338861831 hasConceptScore W2338861831C2779706987 @default.
• W2338861831 hasConceptScore W2338861831C42219234 @default.
• W2338861831 hasConceptScore W2338861831C54355233 @default.
• W2338861831 hasConceptScore W2338861831C71924100 @default.
• W2338861831 hasConceptScore W2338861831C86803240 @default.
• W2338861831 hasConceptScore W2338861831C98274493 @default.
• W2338861831 hasIssue "02" @default.
• W2338861831 hasLocation W23388618311 @default.
• W2338861831 hasOpenAccess W2338861831 @default.
• W2338861831 hasPrimaryLocation W23388618311 @default.
• W2338861831 hasRelatedWork W1595068136 @default.
• W2338861831 hasRelatedWork W1969203417 @default.
• W2338861831 hasRelatedWork W2019932867 @default.
• W2338861831 hasRelatedWork W2037358675 @default.
• W2338861831 hasRelatedWork W2041652033 @default.
• W2338861831 hasRelatedWork W2045447182 @default.
• W2338861831 hasRelatedWork W2054297002 @default.
• W2338861831 hasRelatedWork W2084989677 @default.
• W2338861831 hasRelatedWork W2498044695 @default.
• W2338861831 hasRelatedWork W2705607436 @default.
• W2338861831 hasVolume "04" @default.
• W2338861831 isParatext "false" @default.
• W2338861831 isRetracted "false" @default.
• W2338861831 magId "2338861831" @default.
• W2338861831 workType "article" @default.